Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L McClean

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
BMC Medical Informatics and Decision Making|October 7, 2022
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitalsAlok Joshi, Stephen Todd, David P Finn, et al.
British Journal of Pharmacology|August 13, 2008
(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapyP L McClean, N Irwin, K Hunter, et al.
Neuroscience|January 30, 2026
Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's diseasePaul Denver, Aisling Duffy, Rebecca T Kennedy, et al.
Scientific Reports|March 7, 2026
Multimorbidity trajectories and their sex-specific impacts on risk of mortality and re-hospitalisationMatthew Ennis, Paula L McClean, Priyank Shukla, et al.
Diabetes, Obesity & Metabolism|March 13, 2008
Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIPP L McClean, V A Gault, N Irwin, et al.
Diabetologia|June 15, 2007
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria dietsV A Gault, P L McClean, R S Cassidy, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
Multi-time-point data preparation robustly reveals MCI and dementia risk factorsDaman Kaur, Magda Bucholc, David P Finn, et al.
Microcirculation (New York, N.Y. : 1994)|January 6, 2015
Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™Patricia Kelly, Paula L McClean, Maximilian Ackermann, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2024
Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort StudyDaman Preet Kaur, Magda Bucholc, David P Finn, et al.
Pancreas|June 19, 2007
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetesVictor A Gault, Paula L McClean, Nigel Irwin, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
BMC Medical Informatics and Decision Making|October 7, 2022
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitalsAlok Joshi, Stephen Todd, David P Finn, et al.
British Journal of Pharmacology|August 13, 2008
(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapyP L McClean, N Irwin, K Hunter, et al.
Neuroscience|January 30, 2026
Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's diseasePaul Denver, Aisling Duffy, Rebecca T Kennedy, et al.
Scientific Reports|March 7, 2026
Multimorbidity trajectories and their sex-specific impacts on risk of mortality and re-hospitalisationMatthew Ennis, Paula L McClean, Priyank Shukla, et al.
Diabetes, Obesity & Metabolism|March 13, 2008
Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIPP L McClean, V A Gault, N Irwin, et al.
Diabetologia|June 15, 2007
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria dietsV A Gault, P L McClean, R S Cassidy, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
Multi-time-point data preparation robustly reveals MCI and dementia risk factorsDaman Kaur, Magda Bucholc, David P Finn, et al.
Microcirculation (New York, N.Y. : 1994)|January 6, 2015
Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™Patricia Kelly, Paula L McClean, Maximilian Ackermann, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2024
Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort StudyDaman Preet Kaur, Magda Bucholc, David P Finn, et al.
Pancreas|June 19, 2007
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetesVictor A Gault, Paula L McClean, Nigel Irwin, et al.
Pageof 8